{
    "key_points": [
        "Altmann cautions against considering oneself safe 14 days after the first vaccine dose, mentioning that early signs of efficacy are not definitive proof of immunity.",
        "Professor Nachman Ash criticized Pfizer's estimate of the single dose's effectiveness, a stance that has faced widespread criticism.",
        "The Israeli study found a 33% effectiveness in preventing infection after a single dose, differing from Pfizer's 52% figure in symptom prevention.",
        "Clalit's study results on vaccine effectiveness are not peer-reviewed and were based on observations two weeks post-vaccination.",
        "The Oxford-AstraZeneca vaccine shows 64.1% protection after one dose, with varying effectiveness based on dosing strategy.",
        "AstraZeneca's phase III trial data indicates 70% protection against mild or moderate illness after one dose, extending several months before a booster is needed.",
        "Moderna claims 80.2% efficacy after one dose from FDA submission, with no data on long-term immunity from a single dose.",
        "Sinovac's CoronaVac shows varied efficacy in trials across Turkey, Indonesia, and Brazil but lacks single dose data.",
        "Sinopharm's BBIBP-CorV vaccine has been claimed to be 79% effective after two doses, without international verification.",
        "UAE claims Sinopharm vaccine to be 86% effective according to a press release, with no details on single dose protection."
    ],
    "spokespersons": [
        "Altmann",
        "Professor Nachman Ash (coordinated Israel's Covid-19 response)"
    ],
    "article_type": "general reporting",
    "dateline": "",
    "audience": "general public",
    "stance": "neutral"
}